A Phase II Single-Arm Multi-Center Trial Evaluating the Efficacy of Pembrolizumab in the Treatment of Subjects With Incurable Platinum-Refractory Germ Cell Tumors: Hoosier Cancer Research Network GU14-206
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Therapeutic Use
- 06 Jun 2017 Results (n=12) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 01 Feb 2017 Planned End Date changed from 1 Jan 2019 to 31 Jan 2019.
- 01 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 31 Oct 2017.